Analysts Set Integer Holdings Corporation (NYSE:ITGR) Price Target at $98.38

Integer Holdings Corporation (NYSE:ITGR) has received a consensus rating of “Hold” from the eleven brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $98.3750.

A number of brokerages have recently weighed in on ITGR. Benchmark reaffirmed a “hold” rating on shares of Integer in a report on Friday, October 24th. Raymond James Financial restated an “outperform” rating and set a $95.00 target price (down from $143.00) on shares of Integer in a research note on Friday, October 24th. Piper Sandler decreased their price target on Integer from $155.00 to $82.00 and set an “overweight” rating on the stock in a research note on Friday, October 24th. Truist Financial upped their price objective on Integer from $86.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Finally, Citigroup raised their price objective on Integer from $69.00 to $75.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th.

Integer Stock Down 0.5%

ITGR stock opened at $85.64 on Friday. Integer has a 52 week low of $62.00 and a 52 week high of $144.76. The business has a 50-day simple moving average of $79.31 and a 200 day simple moving average of $90.10. The company has a quick ratio of 2.45, a current ratio of 3.71 and a debt-to-equity ratio of 0.70. The company has a market cap of $3.00 billion, a PE ratio of 35.83, a price-to-earnings-growth ratio of 0.79 and a beta of 0.77.

Integer announced that its board has authorized a share repurchase plan on Tuesday, November 4th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 8.3% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Insider Activity at Integer

In related news, EVP Diron Smith acquired 1,116 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was acquired at an average cost of $67.19 per share, for a total transaction of $74,984.04. Following the transaction, the executive vice president directly owned 7,698 shares in the company, valued at $517,228.62. This trade represents a 16.96% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Tommy P. Thomas sold 884 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $70.15, for a total transaction of $62,012.60. Following the completion of the sale, the vice president owned 3,596 shares in the company, valued at $252,259.40. This represents a 19.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 2.16% of the company’s stock.

Hedge Funds Weigh In On Integer

A number of institutional investors and hedge funds have recently bought and sold shares of the company. CWM LLC lifted its holdings in Integer by 46.1% during the second quarter. CWM LLC now owns 355 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 112 shares during the last quarter. Salomon & Ludwin LLC lifted its stake in shares of Integer by 46.8% during the 4th quarter. Salomon & Ludwin LLC now owns 370 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 118 shares in the last quarter. Orion Porfolio Solutions LLC boosted its holdings in Integer by 1.4% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 9,755 shares of the medical equipment provider’s stock worth $1,200,000 after buying an additional 138 shares during the period. Ameritas Investment Partners Inc. grew its stake in Integer by 4.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,521 shares of the medical equipment provider’s stock valued at $433,000 after buying an additional 148 shares in the last quarter. Finally, Heritage Family Offices LLP raised its holdings in Integer by 4.9% during the 3rd quarter. Heritage Family Offices LLP now owns 3,443 shares of the medical equipment provider’s stock valued at $356,000 after acquiring an additional 160 shares during the period. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer News Summary

Here are the key news stories impacting Integer this week:

• Neutral Sentiment: Lead‑plaintiff deadline (Feb 9, 2026) is approaching — several firms are reminding eligible investors to file to be considered lead plaintiff, a procedural development that consolidates investor claims but does not itself change Integer’s operations. Rosen Law Firm Deadline Notice
• Negative Sentiment: Multiple law firms (Gross, Levi & Korsinsky, Glancy, Pomerantz, Kahn Swick & Foti, BFA Law, Rosen, others) have announced filings or investor alerts — this creates a persistent legal overhang, increases the likelihood of discovery/expenses and raises the prospect of monetary damages or settlements. Investors should expect increased volatility and potential dilution of management focus. Gross Law Firm Notice
• Negative Sentiment: Some plaintiff notices specifically allege overstated demand and link the class action to a prior ~32% stock decline — allegations like these, if substantiated, could lead to sizeable claims and reputational damage. Watch for complaints, motions to dismiss, and any company rebuttal. KSF Notice re: Overstated Demand
• Negative Sentiment: Investor‑oriented coverage calls out operational issues: a Seeking Alpha piece highlights poor uptake of certain products as a driver of the stock’s weakness — that raises real fundamental risk to revenue and margins beyond the legal exposure. Monitor upcoming sales/volume trends and guidance. Seeking Alpha: Product Uptake
• Negative Sentiment: Proliferation of law‑firm notices (Rosen, Levi & Korsinsky, Pomerantz, Berger Montague, BFA, Frank R. Cruz, etc.) amplifies the narrative risk and could pressure valuation multiples until resolution or clearer disclosure from Integer. Levi & Korsinsky Notice

About Integer

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.